How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
40
CRMD Quote, Financials, Valuation and Earnings
Last price:
$7.68
Seasonality move
:
2.79%
Day range:
$7.40 - $7.72
52-week range:
$5.60 - $17.43
Dividend yield:
0%
P/E ratio:
3.75x
P/S ratio:
2.59x
P/B ratio:
1.62x
Volume:
1.6M
Avg. volume:
3.5M
1-year change:
-26.76%
Market cap:
$605.9M
Revenue:
$43.5M
EPS (TTM):
$2.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.34% | 90.44% | $14.86 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$232.2M | $2.01 | 5.9% | 130.85% | $110.38 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$111.5M | $0.09 | 49.53% | -88.43% | $31.75 |
|
CSTL
Castle Biosciences, Inc.
|
$80.4M | -$0.24 | -12.07% | -55.29% | $48.57 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.36% | 40.11% | $28.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRMD
CorMedix, Inc.
|
$7.69 | $14.86 | $605.9M | 3.75x | $0.00 | 0% | 2.59x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$81.84 | $110.38 | $1.8B | 50.19x | $0.00 | 0% | 2.00x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$27.32 | $31.75 | $3.3B | -- | $0.00 | 0% | 10.97x |
|
CSTL
Castle Biosciences, Inc.
|
$32.75 | $48.57 | $955.9M | 30.24x | $0.00 | 0% | 2.80x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.30 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.32x |
|
PFE
Pfizer Inc.
|
$27.22 | $28.71 | $154.8B | 20.09x | $0.43 | 6.32% | 2.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.779 | 30.7% | 2.40x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.523 | 5.02% | 3.07x |
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 0.721 | 5.59% | 6.09x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
CorMedix, Inc. vs. Competitors
-
Which has Higher Returns CRMD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.59%. CorMedix, Inc.'s return on equity of 95.25% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CRMDCorMedix, Inc.89.26% $1.26 $378.5M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CRMD or ANIP?
CorMedix, Inc. has a consensus price target of $14.86, signalling upside risk potential of 93.2%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 34.87%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRMDCorMedix, Inc.4 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CRMD or ANIP More Risky?
CorMedix, Inc. has a beta of 1.388, which suggesting that the stock is 38.76% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 50.037%.
-
Which is a Better Dividend Stock CRMD or ANIP?
CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRMD or ANIP?
CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. CorMedix, Inc.'s net income of $108.6M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.75x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.59x versus 2.00x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M ANIPANI Pharmaceuticals, Inc.2.00x 50.19x $227.8M $24.1M
-
Which has Higher Returns CRMD or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 7.47%. CorMedix, Inc.'s return on equity of 95.25% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital CRMDCorMedix, Inc.89.26% $1.26 $378.5M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About CRMD or ARQT?
CorMedix, Inc. has a consensus price target of $14.86, signalling upside risk potential of 93.2%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.75 which suggests that it could grow by 16.22%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRMDCorMedix, Inc.4 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is CRMD or ARQT More Risky?
CorMedix, Inc. has a beta of 1.388, which suggesting that the stock is 38.76% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.702, suggesting its more volatile than the S&P 500 by 70.199%.
-
Which is a Better Dividend Stock CRMD or ARQT?
CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRMD or ARQT?
CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. CorMedix, Inc.'s net income of $108.6M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.75x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.59x versus 10.97x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M ARQTArcutis Biotherapeutics, Inc.10.97x -- $99.2M $7.4M
-
Which has Higher Returns CRMD or CSTL?
Castle Biosciences, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of -0.6%. CorMedix, Inc.'s return on equity of 95.25% beat Castle Biosciences, Inc.'s return on equity of -2.71%.
Company Gross Margin Earnings Per Share Invested Capital CRMDCorMedix, Inc.89.26% $1.26 $378.5M CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M -
What do Analysts Say About CRMD or CSTL?
CorMedix, Inc. has a consensus price target of $14.86, signalling upside risk potential of 93.2%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $48.57 which suggests that it could grow by 48.31%. Given that CorMedix, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRMDCorMedix, Inc.4 0 0 CSTLCastle Biosciences, Inc.8 0 0 -
Is CRMD or CSTL More Risky?
CorMedix, Inc. has a beta of 1.388, which suggesting that the stock is 38.76% more volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.16%.
-
Which is a Better Dividend Stock CRMD or CSTL?
CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRMD or CSTL?
CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. CorMedix, Inc.'s net income of $108.6M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.75x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.59x versus 2.80x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K
-
Which has Higher Returns CRMD or FOLD?
Amicus Therapeutics, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.24%. CorMedix, Inc.'s return on equity of 95.25% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital CRMDCorMedix, Inc.89.26% $1.26 $378.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About CRMD or FOLD?
CorMedix, Inc. has a consensus price target of $14.86, signalling upside risk potential of 93.2%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.4%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRMDCorMedix, Inc.4 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is CRMD or FOLD More Risky?
CorMedix, Inc. has a beta of 1.388, which suggesting that the stock is 38.76% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock CRMD or FOLD?
CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRMD or FOLD?
CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. CorMedix, Inc.'s net income of $108.6M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.75x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.59x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M
-
Which has Higher Returns CRMD or PFE?
Pfizer Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of -9.34%. CorMedix, Inc.'s return on equity of 95.25% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital CRMDCorMedix, Inc.89.26% $1.26 $378.5M PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About CRMD or PFE?
CorMedix, Inc. has a consensus price target of $14.86, signalling upside risk potential of 93.2%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 5.48%. Given that CorMedix, Inc. has higher upside potential than Pfizer Inc., analysts believe CorMedix, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRMDCorMedix, Inc.4 0 0 PFEPfizer Inc.7 15 1 -
Is CRMD or PFE More Risky?
CorMedix, Inc. has a beta of 1.388, which suggesting that the stock is 38.76% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock CRMD or PFE?
CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.32% to investors and pays a quarterly dividend of $0.43 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios CRMD or PFE?
CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. CorMedix, Inc.'s net income of $108.6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.75x while Pfizer Inc.'s PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.59x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M PFEPfizer Inc.2.48x 20.09x $17.6B -$1.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
